Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 15, 2025International journal of research and scientific innovationOpen Access

QR-Specialized Information Guidance Nexus (QR-SIGN): Enhancing OTC Medication knowledge and Adherence of the Deaf Community

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAdolf D. AmoloriaJEJewel Lyre V. EbonDFDonna D. French

Discussion

Loading...

Member takes

Overview

Quasi-experimental study shows QR-SIGN enhances knowledge and adherence to OTC medications in Deaf community.

Key Points

  • Significant improvements in knowledge scores were observed in the intervention group, indicating increased understanding of OTC medications.
  • Participants using QR-SIGN reported adherence scores improving from 2.95 to 3.72, showing better compliance with medication instructions.
  • The study utilized a quasi-experimental, non-randomized pretest-posttest design with 30 Deaf participants divided into intervention and control groups.
  • These results highlight the potential for QR code technology to improve health outcomes and user satisfaction among Deaf individuals.

Cite This Study

Amoloria et al. (2025) studied this question.

synapsesocial.com/papers/68efa18f9d05deea71d13e46https://doi.org/10.51244/ijrsi.2025.120800344
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness of VoxQR (Voice QR Code) In Enhancing Knowledge Medication Adherence for Geriatric Hypertensive Patients in Koronadal City2025
  2. 2Quick response codes for management of systemic diseases in dental clinics2025
  3. 3Patient Engagement and Feasibility of a QR Code–Based Digital Information Tool in the Emergency Department2026
  4. 4FP8.5 - QR Coded Patient Leaflets – Transforming the Sustainability of Patient Information Delivery in the Surgical Outpatient Department2024
  5. 5606P Reproductive system disorders during targeted therapies for breast cancer: A pharmacovigilance analysis2026